Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.55 |
| ▸ | CCR8 | P51685 | 4/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 3/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11808148 | 0.80 | COMT (0.61) | CCR1CCR8HSP90AA1HSP90AB1CCR5 | |
| SCHEMBL874272 | 0.80 | PSMD14 (0.67) | CCR1CCR8HSP90AA1PSMD14COPS5 | |
| SCHEMBL12093369 | 0.78 | CCR1 (0.56) | CCR1CCR8HSP90AA1PSMD14COPS5 | |
| SCHEMBL29956211 | 0.78 | HSP90AA1 (0.51) | CCR1CCR8HSP90AA1HSP90AB1PSMD14 | |
| SCHEMBL14242732 | 0.77 | HSP90AA1 (0.54) | CCR1CCR8HSP90AA1HSP90AB1CCR5 | |
| SCHEMBL2938512 | 0.77 | LMNA (0.56) | CCR1CCR8HSP90AA1HSP90AB1PSMD14 | |
| SCHEMBL3582732 | 0.77 | CCR1 (0.55) | CCR1CCR8HSP90AA1PSMD14COPS5 | |
| SCHEMBL19001540 | 0.77 | CCR1 (0.55) | CCR1CCR8HSP90AA1PSMD14COPS5 | |
| SCHEMBL3565423 | 0.77 | ALDH1A1 (0.58) | CCR1CCR8HSP90AA1HSP90AB1CCR5 | |
| SCHEMBL7441724 | 0.77 | HSP90AA1 (0.54) | CCR1CCR8HSP90AA1HSP90AB1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| EP-3283462-B1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| WO-2016168540-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0261539-B1 | SUBSTITUTED PHENYL-SULPHON AMIDES | BAYER AG (DE) | 1991-03-06 | — | — | EP | disclosed |
| EP-0261539-A2 | Substituted phenyl-sulphon amides | BAYER AG (DE) | 1988-03-30 | — | — | EP | disclosed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CCR1 564/4885CCR8 1018/4885HSP90AA1 2426/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | CCR1 1272/4885CCR8 2264/4885HSP90AA1 4078/4885 |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | CCR1 1088/4885CCR8 2196/4885HSP90AA1 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.